Kaken Pharmaceutical (4521) · InitiativeRestated
Growth strategy and value maximization for Polyoxin
First written in FY2025-H1. 2 of 3 entries say "Restated". Latest entry: FY2026.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
Growth and value maximization of the agrochemical business centered on PolyoxinA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2026RestatedAnnual report
「In the agricultural chemicals business, the Company is working to maximize value based on a growth strategy for Polyoxin, its core microbial-derived natural-product pesticide.」
The policy of making Polyoxin a core element of the growth strategy and maximizing its value has been reconfirmed, and the fiscal year disclosure also included revenue growth in the agricultural chemicals business due to higher sales of metamifop and other products. - FY2026-H1RestatedAnnual report
「In the agricultural chemicals business, the Company is working to maximize value based on a growth strategy for Polyoxin, its core microbial-derived natural-product pesticide.」
The policy of making Polyoxin a core element of the growth strategy and maximizing its value has been reconfirmed. The current interim period also included disclosure of revenue growth in the agricultural chemicals business due to higher overseas sales of Polyoxin. - FY2025-H1First statedAnnual report
「In the agricultural chemicals business, the Company is working to maximize value based on a growth strategy for Polyoxin, its core microbial-derived natural-product pesticide.」
The policy of making the microbial-derived natural-product pesticide Polyoxin a core element of the growth strategy and maximizing product value was disclosed for the first time in the agricultural chemicals business.